Comparison of antibody levels and protective efficacy against pneumococci in two immunoglobulin preparations for intravenous use.
Passive immunization with modern intravenous immunoglobulin preparations might be used prophylactically in individuals at extreme risk of contracting postsplenectomy sepsis or therapeutically in established infections. Since pneumococci are the predominant causative organisms, we determined antibodies against 14 pneumococcal serotypes in two commercially available immunoglobulin preparations (two batches of each) using enzyme-linked immunosorbent assay. The four batches were remarkably similar in antibody content. Low levels against some clinically important serotypes, i.e. types 3, 8 and 18C were recorded. The protective effect of one batch of each preparation against type 1 pneumococci was documented in splenectomized rats.
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis*; D001428:Bacterial Vaccines / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous; D008297:Male; D022242:Pneumococcal Vaccines; D051381:Rats; D011919:Rats, Inbred Strains; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D022242:Pneumococcal Vaccines